A new therapeutic approach in the medical treatment of Cushing’s syndrome: glucocorticoid receptor blockade with mifepristone.
Fleseriu et al. • 2013 • Endocr Pract. 2013;19(2):313-26.
© 2024 Corcept Therapeutics, Incorporated
Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology.
Baglietto-Vargas et al. • 2013 • Biol Psychiatry. 2013;74(5):357-66.
A single-day treatment with mifepristone is sufficient to normalize chronic glucocorticoid induced suppression of hippocampal cell proliferation.
Hu et al. • 2012 • PLoS One. 2012;7(9):e46224.
Acute effects of neonatal dexamethasone treatment on proliferation and astrocyte immunoreactivity in hippocampus and corpus callosum: towards a rescue strategy.
Claessens et al. • 2012 • Brain Res. 2012;1482:1-12.
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome.
Fleseriu et al. • 2012 • J Clin Endocrinol Metab. 2012;97(6):2039-49.
Administration of Glucocorticoids to Ovarian Cancer Patients Is Associated with Expression of the Anti-apoptotic Genes SGK1 and MKP1/DUSP1 in Ovarian Tissues
Melhem et al • 2009 • Clin Cancer Res.
Slowing the progression of cognitive decline in Alzheimer’s disease using mifepristone.
Belanoff et al. • 2002 • J Mol Neurosci. 2002;19(1-2):201-6.
Successful long-term treatment of refractory Cushing’s disease with high-dose mifepristone (RU 486).
Chu et al. • 2001 • J Clin Endocrinol Metab. 2001;86(8):3568-73.